ÂÜÀòÂÒÂ×

Michael Huang is a US-trained clinical drug development executive with a foundation in primary care medicine and extensive experience in developing small molecules, biologics, and oligonucleotide therapeutics. They have held leadership roles across various areas of clinical development, including Vice President of Clinical Development at Regulus Therapeutics and Chief Medical Officer at multiple organizations, such as Spruce Biosciences and DTx Pharma. Huang’s therapeutic expertise encompasses a wide range of fields, including rare diseases, oncology, and neurology, and they currently serve as a Board Member for the Huntington Study Group. Their educational background includes a Doctor of Medicine from Rosalind Franklin University and a BA in Molecular and Cell Biology from the University of California, Berkeley.